Labcorp (LH)
(Delayed Data from NYSE)
$207.94 USD
-0.03 (-0.01%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $207.95 +0.01 (0.00%) 7:30 PM ET
2-Buy of 5 2
A Value C Growth B Momentum A VGM
Company Summary
Headquartered in Burlington, NC, Laboratory Corporation of America Holdings or Labcorp is a leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to-end drug development support. In 2015, Labcorp acquired NJ based Covance, a drug development services company providing a wide range of early stage and late-stage product development services on a worldwide basis primarily to the pharmaceutical and biotechnology industries.
In July 2022, Labcorp’s Board authorized a spin-off of its wholly owned CDCS (Clinical Development and Commercialization Services) business to its shareholders through a tax-free transaction. In February 2023, the company unveiled the ...
Company Summary
Headquartered in Burlington, NC, Laboratory Corporation of America Holdings or Labcorp is a leading healthcare diagnostics company, providing comprehensive clinical laboratory services and end-to-end drug development support. In 2015, Labcorp acquired NJ based Covance, a drug development services company providing a wide range of early stage and late-stage product development services on a worldwide basis primarily to the pharmaceutical and biotechnology industries.
In July 2022, Labcorp’s Board authorized a spin-off of its wholly owned CDCS (Clinical Development and Commercialization Services) business to its shareholders through a tax-free transaction. In February 2023, the company unveiled the name of the future independent clinical development business, Fortrea, and successfully completed the spin-off on Jun 30, 2023
.
Following this development, Labcorp reports its laboratory service business under two segments —
Diagnostics Laboratories (Dx) comprised 77% of the company’s revenues in 2023, up 2.2% from 2022. The segment offers a comprehensive menu of frequently requested core testing and specialty testing through an integrated network of primary and specialty laboratories across the United States and Canada. It also offers consumer-initiated wellness testing available online through its Labcorp OnDemand platform.
Biopharma Laboratory Services (“BLS”) (23% of net sales, up 2.8%): This includes the remaining operations of the previously reported Drug Development segment. Biopharma laboratory services consist of two businesses — the Central Laboratories business, which represents about 70% of the segment’s revenues, and Early Development Research Laboratories, smaller in proportion but a leader in the market.
General Information
Labcorp
358 South Main Street
BURLINGTON, NC 27215
Phone: 336-229-1127
Fax: 336-513-4510
Email: investor@labcorp.com
Industry | Medical - Dental Supplies |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Earnings Date | 4/25/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 3.46 |
Current Year EPS Consensus Estimate | 14.84 |
Estimated Long-Term EPS Growth Rate | 9.00 |
Earnings Date | 4/25/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 207.97 |
52 Week High | 234.09 |
52 Week Low | 178.57 |
Beta | 1.01 |
20 Day Moving Average | 652,843.31 |
Target Price Consensus | 242.00 |
4 Week | -2.60 |
12 Week | -8.12 |
YTD | -8.50 |
4 Week | 0.13 |
12 Week | -11.02 |
YTD | -14.95 |
Shares Outstanding (millions) | 84.13 |
Market Capitalization (millions) | 17,495.66 |
Short Ratio | NA |
Last Split Date | 5/13/2002 |
Dividend Yield | 1.38% |
Annual Dividend | $2.88 |
Payout Ratio | 0.21 |
Change in Payout Ratio | 0.15 |
Last Dividend Payout / Amount | 2/26/2024 / $0.72 |
Fundamental Ratios
P/E (F1) | 14.01 |
Trailing 12 Months | 14.94 |
PEG Ratio | 1.56 |
vs. Previous Year | -20.29% |
vs. Previous Quarter | -2.37% |
vs. Previous Year | -17.44% |
vs. Previous Quarter | -0.77% |
Price/Book | 2.24 |
Price/Cash Flow | 10.23 |
Price / Sales | 1.36 |
3/31/24 | NA |
12/31/23 | 13.99 |
9/30/23 | 14.09 |
3/31/24 | NA |
12/31/23 | 6.82 |
9/30/23 | 6.97 |
3/31/24 | NA |
12/31/23 | 1.17 |
9/30/23 | 1.36 |
3/31/24 | NA |
12/31/23 | 1.02 |
9/30/23 | 1.20 |
3/31/24 | NA |
12/31/23 | 9.46 |
9/30/23 | 9.65 |
3/31/24 | NA |
12/31/23 | 3.24 |
9/30/23 | 4.88 |
3/31/24 | NA |
12/31/23 | 4.68 |
9/30/23 | 4.75 |
3/31/24 | NA |
12/31/23 | 92.76 |
9/30/23 | 92.73 |
3/31/24 | NA |
12/31/23 | 18.47 |
9/30/23 | 18.36 |
3/31/24 | NA |
12/31/23 | 0.52 |
9/30/23 | 0.57 |
3/31/24 | NA |
12/31/23 | 34.51 |
9/30/23 | 36.51 |